SNTI Senti Biosciences Holdings, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%
Returns
ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19,000 | $17,000 | $16,000 | $22,000 | $0 | $0 | $0 | $0 |
| R&D expense | $6.07M | $7.77M | $5.28M | $7.76M | $10.52M | $10.03M | $9.28M | $7.77M |
| SG&A expense | $6.27M | $6.74M | $6.23M | $5.85M | $6.43M | $6.77M | $7.12M | $8.39M |
| Operating income | -$12.32M | -$14.49M | -$4.62M | -$18.64M | -$16.95M | -$16.80M | -$16.40M | -$16.17M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$11.59M | -$12.75M | -$4.22M | -$14.47M | -$18.13M | -$14.73M | -$14.11M | -$610,000 |
| EBITDA | -$11.67M | -$13.82M | -$3.93M | -$17.74M | -$16.04M | -$15.88M | -$15.47M | -$15.23M |
| EPS (basic) | -0.37 | -0.41 | -0.14 | — | -0.69 | -0.56 | -1.41 | — |
| EPS (diluted) | -0.37 | -0.41 | -0.14 | — | -0.69 | -0.56 | -1.41 | — |
| Weighted avg. shares (diluted) | 31.15M | 31.14M | 30.97M | — | 26.23M | 26.08M | 10.01M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.55M | $6.46M | $8.94M | $16.42M | $15.78M | $25.11M | $37.35M | $51.81M |
| Current assets | $9.52M | $13.01M | $14.79M | $23.27M | $18.16M | $32.52M | $45.21M | $58.96M |
| PP&E, net | $10.77M | $11.43M | $12.10M | $12.89M | $18.69M | $19.59M | $20.53M | $21.29M |
| Total assets | $28.36M | $33.10M | $38.24M | $51.22M | $52.69M | $68.54M | $82.78M | $97.84M |
| Current liabilities | $17.59M | $15.77M | $14.27M | $13.97M | $12.03M | $9.99M | $10.73M | $13.15M |
| Total liabilities | $37.96M | $36.51M | $35.68M | $45.63M | $44.56M | $43.89M | $44.92M | $47.09M |
| Shareholders' equity | -$9.60M | -$3.40M | $2.56M | $5.59M | $8.12M | $24.65M | $37.86M | $25.65M |
| Shares outstanding | 31.15M | 31.14M | 31.14M | 30.88M | 26.29M | 26.16M | 26.00M | 4.83M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.73M | -$14.25M | -$7.48M | -$6.88M | -$9.45M | -$13.07M | -$14.05M | -$13.50M |
| Capital expenditure | $0 | — | — | $0 | $0 | $196,000 | $0 | $11,000 |
| Free cash flow | -$6.73M | — | — | -$6.88M | -$9.45M | -$13.27M | -$14.05M | -$13.52M |
| Investing cash flow | $0 | $0 | $114,000 | $0 | $0 | -$184,000 | $0 | -$11,000 |
| Financing cash flow | $5.82M | $9.68M | -$118,000 | $11.04M | $124,000 | $1.01M | -$414,000 | $51.29M |
| Depreciation & amortization | $650,000 | $667,000 | $688,000 | $893,000 | $904,000 | $914,000 | $926,000 | $937,000 |
| Stock-based compensation | $961,000 | $1.05M | $1.31M | $1.43M | $1.55M | $1.53M | $1.20M | $605,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.